Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (NCT06074588)
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypothesis is that sacituzumab tirumotecan is superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.
Who can join: Review the eligibility criteria below.
Location: UCLA Hematology/Oncology - Santa Monica ( Site 0023) — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (195 Sites)
Showing the first 25 of 195 sites.
- UCLA Hematology/Oncology - Santa Monica ( Site 0023) — Los Angeles, California
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0001) — Jacksonville, Florida
- Mid Florida Hematology and Oncology Center ( Site 0005) — Orange City, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) — Marietta, Georgia
- Karmanos Cancer Institute ( Site 0018) — Detroit, Michigan
- Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0027) — Rochester, Minnesota
- Hattiesburg Clinic Hematology/Oncology ( Site 0010) — Hattiesburg, Mississippi
- University Of Nebraska Medical Center ( Site 0011) — Omaha, Nebraska
- Englewood Hospital and Medical Center ( Site 0033) — Englewood, New Jersey
- Atlantic Health System Morristown Medical Center ( Site 0031) — Morristown, New Jersey
- Capital Health Medical Center - Hopewell ( Site 0006) — Pennington, New Jersey
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0015) — Cincinnati, Ohio
- Tennessee Oncology Chattanooga (Site 0038) — Chattanooga, Tennessee
- Tennessee Oncology (0036) — Nashville, Tennessee
- University of Texas MD Anderson (0037) — Houston, Texas
- VCU Health Adult Outpatient Pavillion ( Site 0026) — Richmond, Virginia
- St. George Private Hospital ( Site 3004) — Kogarah, New South Wales
- Westmead Hospital ( Site 3000) — Westmead, New South Wales
- Monash Health-Oncology Research ( Site 3001) — Clayton, Victoria
- Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 3003) — Melbourne, Victoria
- Hospital Santa Rita de Cassia (Site 0449) — Vitória, Espírito Santo
- Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0447) — Natal, Rio Grande do Norte
- Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0440) — Porto Alegre, Rio Grande do Sul
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0444) — Barretos, São Paulo
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica (Site 0448) — São Paulo,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.